Equal Expansion of Endogenous Transplant-Specific Regulatory T Cell and Recruitment Into the Allograft During Rejection and Tolerance
Overview
Affiliations
Despite numerous advances in the definition of a role for regulatory T cells (Tregs) in facilitating experimental transplantation tolerance, and ongoing clinical trials for Treg-based therapies, critical issues related to the optimum dosage, antigen-specificity, and Treg-friendly adjunct immunosuppressants remain incompletely resolved. In this study, we used a tractable approach of MHC tetramers and flow cytometry to define the fate of conventional (Tconvs) and Tregs CD4 T cells that recognize donor 2W antigens presented by I-A on donor and recipient antigen-presenting cells (APCs) in a mouse cardiac allograft transplant model. Our study shows that these endogenous, donor-reactive Tregs comparably accumulate in the spleens of recipients undergoing acute rejection or exhibiting costimulation blockade-induced tolerance. Importantly, this expansion was not detected when analyzing bulk splenic Tregs. Systemically, the distinguishing feature between tolerance and rejection was the inhibition of donor-reactive conventional T cell (Tconv) expansion in tolerance, translating into increased percentages of splenic FoxP3 Tregs within the 2W:I-A CD4 T cell subset compared to rejection (~35 vs. <5% in tolerance vs. rejection). We further observed that continuous administration of rapamycin, cyclosporine A, or CTLA4-Ig did not facilitate donor-specific Treg expansion, while all three drugs inhibited Tconv expansion. Finally, donor-specific Tregs accumulated comparably in rejecting tolerant allografts, whereas tolerant grafts harbored <10% of the donor-specific Tconv numbers observed in rejecting allografts. Thus, ~80% of 2W:I-A CD4 T cells in tolerant allografts expressed FoxP3 compared to ≤10% in rejecting allografts. A similar, albeit lesser, enrichment was observed with bulk graft-infiltrating CD4 cells, where ~30% were FoxP3 in tolerant allografts, compared to ≤10% in rejecting allografts. Finally, we assessed that the phenotype of 2W:I-A Tregs and observed that the percentages of cells expressing neuropilin-1 and CD73 were significantly higher in tolerance compared to rejection, suggesting that these Tregs may be functionally distinct. Collectively, the analysis of donor-reactive, but not of bulk, Tconvs and Tregs reveal a systemic signature of tolerance that is stable and congruent with the signature within tolerant allografts. Our data also underscore the importance of limiting Tconv expansion for high donor-specific Tregs:Tconv ratios to be successfully attained in transplantation tolerance.
Kim G, Nam K, Choi J Clin Transplant Res. 2024; 38(4):326-340.
PMID: 39690903 PMC: 11732762. DOI: 10.4285/ctr.24.0057.
Tregs in transplantation tolerance: role and therapeutic potential.
Cassano A, Chong A, Alegre M Front Transplant. 2024; 2:1217065.
PMID: 38993904 PMC: 11235334. DOI: 10.3389/frtra.2023.1217065.
McIntosh C, Allocco J, Wang P, McKeague M, Cassano A, Wang Y J Clin Invest. 2023; 133(21).
PMID: 37676735 PMC: 10617766. DOI: 10.1172/JCI168465.
Classic and Current Opinions in Human Organ and Tissue Transplantation.
Oli A, Rowaiye A, Adejumo S, Anazodo F, Ahmad R, Sinha S Cureus. 2022; 14(11):e30982.
PMID: 36337306 PMC: 9624478. DOI: 10.7759/cureus.30982.
Andrade M, Young J, Pollard J, Yin D, Alegre M, Chong A JCI Insight. 2022; 7(11).
PMID: 35674134 PMC: 9220839. DOI: 10.1172/jci.insight.159205.